logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12766096 B1

PDFFull Text
Date of Patent:
Oct. 20, 2026

Filed:

Sep. 15, 2023

High concentration pharmaceutical compositions of roflumilast for ophthalmic delivery

Applicant:

Lolyx Therapeutics, Inc., Burlingame, CA (US);

Inventors:

Richard Graham, Irvine, CA (US);

Elizabeth W. Jeffords, Hillsborough, CA (US);

Hovhannes J. Gukasyan, Orange, CA (US);

Shannon Dahl, Palo Alto, CA (US);

Assignee:

IOLYX THERAPEUTICS, INC., Burlingame, CA (US);

Attorney:

Rothwell, Figg, Ernst & Manbeck, P.C.

Primary Examiner:

Zohreh A Fay

Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 31/44 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0048 (2013.01); A61K 9/0019 (2013.01); A61K 31/44 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01);
Abstract

The present invention relates to high concentration ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast, which are suitable for intravitreal or other ocular administration to injection sites internal or external to the eye and orbit. The compositions can comprise about 2% to about 5% w/v of roflumilast, a viscosity agent, a tonicity agent, a buffer agent, a surfactant, and water. The pharmaceutical compositions are stable with little to no impurities and can be injected from a 27 Gauge or 30 Gauge syringe with minimal force, resulting in therapeutic levels of pharmaceutical in relevant tissues for the ocular surface, anterior compartment, vitreous/posterior compartments, and tissues or chambers surrounding the eye.

Find Patent Forward Citations

Graham, Richard. (2026). High concentration pharmaceutical compositions of roflumilast for ophthalmic delivery (U.S. Patent No. 12766096). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12766096

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…